Lifeboat Foundation

By Helen O’Shea

On a windy, bright day in Lemoore, California another 250 megawatts of clean power was added to California’s energy mix with the dedication of the Aquamarine Solar Project. There are many new solar projects coming online across the country these days, but the Aquamarine project is notable for its innovative development model — it’s part of a 20,000-acre master-planned solar park on fallowed and salt-contaminated agricultural lands in the Westlands Water District in California’s Central Valley.

Disturbed lands farmed for years with no residual habitat value are the perfect place to locate utility-scale solar projects. In 2016 these lands, among many others, were identified as suitable for development by a diverse group of stakeholders through the San Joaquin Valley Least Conflict Solar Planning exercise.

Japanese architecture studios Unemori Architects and Teco Architects have turned a commercial building in Kitakami, Japan, into a health and childcare support centre, adding a new facade as well as undulating floors and ceilings.

On this land taken from Indigenous Peoples, a new nation was eventually born, largely built by those whose ancestries traced back to the Old World via immigration and slavery.

As the country grew, inventions like the telephone, airplane, and Internet helped usher in today’s interconnected world. But the inexorable march of technological progress has come at great cost to the health of the planet, particularly because of global dependence on fossil fuels. The United Nations declared in 2017 that a Decade of Ocean Science for Sustainable Development would be held from 2021 to 2030. This Ocean Decade calls for a worldwide effort to reverse the oceans’ degradation.

The dawn of this decade, 2020, also marked the 400th anniversary of the Mayflower’s journey. Plymouth 400, a cultural nonprofit, has been working for more than a decade to commemorate the anniversary in ways that honor all aspects of this history, said spokesperson Brian Logan. Events began in 2020, but one of the most innovative launches is still waiting in the wings—a newfangled nautical craft, the Mayflower Autonomous Ship, or MAS.

Phase I trial aims to build on response seen in proof-of-concept trial.

NEW YORK AND CAMBRIDGE, MASS. — JANUARY 27, 2022 — IAVI and biotechnology company Moderna announced today that first doses have been administered in a clinical trial of experimental HIV vaccine antigens at George Washington University (GWU) School of Medicine and Health Sciences in Washington, D.C. The Phase I trial, IAVI G002, is designed to test the hypothesis that sequential administration of priming and boosting HIV immunogens delivered by messenger RNA (mRNA) can induce specific classes of B-cell responses and guide their early maturation toward broadly neutralizing antibody (bnAb) development. The induction of bnAbs is widely considered to be a goal of HIV vaccination, and this is the first step in that process. The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna’s mRNA technology.

IAVI and Moderna and do not necessarily reflect the views of USAID or the United States government.

Continue reading “IAVI and Moderna launch trial of HIV vaccine antigens delivered through mRNA technology” »

“Beneficial Viruses” For Human Health, Agriculture And Environmental Sustainability — Dr. Marilyn Roossinck, Ph.D., Professor Emeritus, Penn State

Dr. Marilyn Roossinck Ph.D. (https://plantpath.psu.edu/directory/mjr25) is Professor Emeritus of plant pathology, environmental microbiology and biology at Penn State University.

Continue reading “Dr. Marilyn Roossinck, Ph.D. — Beneficial Viruses — Professor Emeritus, Penn State University” »

Another E5 update. At the moment there is a great difference between the control and treated rats. The treated rats are nearing their expected lifespan. And it looks like E5 human trials are trying to be set up.

In this video we report on the Feb 2022 update from Dr. Katcher’s experiment with E5, where he is testing to see how long the rats will stay alive if they are given an E5 injection every 90 days.

Continue reading “Dr Katcher’s E5 Experiment” »

The machine-learning model could help scientists speed the development of new medicines.

This technique could help scientists better understand some biological processes that involve protein interactions, like DNA replication and repair; it could also speed up the process of developing new medicines.

“Deep learning is very good at capturing interactions between different proteins that are otherwise difficult for chemists or biologists to write experimentally. Some of these interactions are very complicated, and people haven’t found good ways to express them. This deep-learning model can learn these types of interactions from data,” says Octavian-Eugen Ganea, a postdoc in the MIT Computer Science and Artificial Intelligence Laboratory (CSAIL) and co-lead author of the paper.

Continue reading “Artificial intelligence system rapidly predicts how two proteins will attach” »

What are biomarkers? They are medical signals that can measure health in an accurate and reproducible way. Common examples include blood pressure readings, heart rate, and even genetic test results.

Modern digital devices measure several health parameters. Fitbit trackers use sensors such as accelerometers to tell how many steps we’ve taken in a day or how fast we’ve been walking. When can such novel health measures function as medical biomarkers?

Continue reading “The Future Of Medicine: Fighting Deadly Diseases With Smart Devices And Digital Biomarkers” »

𝙎𝙡𝙚𝙚𝙥 𝙢𝙖𝙮 𝙗𝙚 𝙤𝙣𝙚 𝙤𝙛 𝙩𝙝𝙚 𝙢𝙤𝙨𝙩 𝙥𝙤𝙩𝙚𝙣𝙩 𝙢𝙚𝙙𝙞𝙘𝙞𝙣𝙚𝙨 𝙛𝙤𝙧 𝙩𝙝𝙚 𝙗𝙧𝙖𝙞𝙣, 𝙨𝙘𝙞𝙚𝙣𝙩𝙞𝙨𝙩𝙨 𝙖𝙧𝙚 𝙙𝙞𝙨𝙘𝙤𝙫𝙚𝙧𝙞𝙣𝙜, 𝙖𝙨 𝙩𝙝𝙚𝙮 𝙚𝙭𝙥𝙡𝙤𝙧𝙚 𝙩𝙝𝙚 𝙞𝙣𝙣𝙚𝙧 𝙡𝙖𝙗𝙮𝙧𝙞𝙣𝙩𝙝𝙨 𝙤𝙛 𝙩𝙝𝙚 𝙩𝙝𝙧𝙚𝙚-𝙥𝙤𝙪𝙣𝙙 𝙤𝙧𝙜𝙖𝙣 𝙙𝙪𝙧𝙞𝙣𝙜 𝙙𝙚𝙚𝙥 𝙨𝙡𝙚𝙚𝙥 𝙖𝙣𝙙 𝙙𝙧𝙚𝙖𝙢 𝙘𝙮𝙘𝙡𝙚𝙨 𝙞𝙣 𝙗𝙤𝙩𝙝 𝙝𝙚𝙖𝙡𝙩𝙝 𝙖𝙣𝙙 𝙙𝙞𝙨𝙚𝙖𝙨𝙚.

The Neuro-Network.

𝐂𝐚𝐧 𝐝𝐞𝐞𝐩 𝐬𝐥𝐞𝐞𝐩 𝐡𝐞𝐥𝐩 𝐝𝐞𝐯𝐚𝐬𝐭𝐚𝐭𝐢𝐧𝐠 𝐛𝐫𝐚𝐢𝐧 𝐝𝐢𝐬𝐨𝐫𝐝𝐞𝐫𝐬? 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐬𝐭𝐬 𝐬𝐭𝐮𝐝𝐲𝐢𝐧𝐠 𝐏𝐚𝐫𝐤𝐢𝐧𝐬𝐨𝐧’𝐬 𝐰𝐚𝐧𝐭 𝐭𝐨 𝐟𝐢𝐧𝐝 𝐨𝐮𝐭

Continue reading “Can deep sleep help devastating brain disorders? Scientists studying Parkinson’s want to find out” »